Put Options

20 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2023

Jul 18, 2023

BUY
$11.12 - $22.2 $8,896 - $17,760
800 New
800 $1,000
Q4 2022

Feb 07, 2023

BUY
$18.12 - $27.32 $3,624 - $5,464
200 Added 1.17%
17,300 $8,000
Q2 2022

Aug 04, 2022

SELL
$13.15 - $20.45 $59,175 - $92,025
-4,500 Reduced 20.83%
17,100 $81,000
Q1 2022

Apr 14, 2022

SELL
$14.54 - $21.5 $1,454 - $2,150
-100 Reduced 0.46%
21,600 $178,000
Q4 2021

Jan 18, 2022

BUY
$20.24 - $36.01 $252,999 - $450,125
12,500 Added 135.87%
21,700 $166,000
Q3 2021

Oct 26, 2021

BUY
$26.01 - $38.22 $234,090 - $343,980
9,000 Added 4500.0%
9,200 $1,000
Q2 2021

Jul 19, 2021

SELL
$29.97 - $37.17 $23,976 - $29,736
-800 Reduced 80.0%
200 $1,000
Q1 2021

Apr 26, 2021

SELL
$29.24 - $42.03 $70,176 - $100,872
-2,400 Reduced 70.59%
1,000 $7,000
Q4 2020

Jan 21, 2021

BUY
$35.35 - $50.67 $31,815 - $45,603
900 Added 36.0%
3,400 $40,000
Q3 2020

Oct 27, 2020

SELL
$35.98 - $47.66 $967,861 - $1.28 Million
-26,900 Reduced 91.5%
2,500 $39,000
Q2 2020

Jul 22, 2020

SELL
$45.06 - $67.74 $4,506 - $6,773
-100 Reduced 0.34%
29,400 $306,000
Q1 2020

May 07, 2020

BUY
$40.01 - $73.97 $1.14 Million - $2.1 Million
28,400 Added 2581.82%
29,500 $392,000
Q4 2019

Feb 06, 2020

SELL
$37.13 - $74.62 $25,991 - $52,234
-700 Reduced 38.89%
1,100 $7,000
Q3 2019

Oct 28, 2019

BUY
$39.36 - $76.8 $31,488 - $61,440
800 Added 80.0%
1,800 $45,000
Q2 2019

Aug 09, 2019

SELL
$52.76 - $82.19 $63,312 - $98,628
-1,200 Reduced 54.55%
1,000 $13,000
Q1 2019

May 10, 2019

SELL
$27.39 - $68.41 $60,258 - $150,502
-2,200 Reduced 50.0%
2,200 $0
Q4 2018

Feb 05, 2019

BUY
$22.8 - $33.93 $25,080 - $37,323
1,100 Added 33.33%
4,400 $12,000
Q3 2018

Nov 07, 2018

BUY
$29.75 - $43.08 $86,275 - $124,932
2,900 Added 725.0%
3,300 $13,000
Q1 2018

May 11, 2018

SELL
$17.1 - $26.61 $5,130 - $7,983
-300 Reduced 42.86%
400 $0
Q4 2017

Jan 17, 2018

BUY
$9.47 - $19.59 $6,629 - $13,713
700
700 $0

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $732M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.